IV Gentamicin Review after 72hrs of treatment



IV Gentamicin prescriptions should be reviewed 72hrs after start of treatment. It might be appropriate for IV Gentamicin to continue, although higher cumulative doses increase the risk of ototoxicity. For further information see NHS Ayrshire & Arran Gentamicin dosing guidance and FAQs.

DO NOT use this chart if synergistic IV Gentamicin is given for suspected or proven infective endocarditis.

Patient has features of sepsis/septic shock → urgent review by a senior clinician with a view to escalating antimicrobial therapy.

IVOS criteria not met.

No current positive cultures to guide choice of Gentamicin alternative or cultures still in progress.

Patient is stable or improving.

Review current culture results for reported Gentamicin alternatives and follow this IVOS algorithm.



IVOS criteria met.

Switch to reported Gentamicin alternative or use IVOS policy if no positive cultures.

Upper or complicated UTI

Switch to PO Co-trimoxazole* 960mg 12hrly

Hospital-acquired Pneumonia (HAP)

STOP Gentamicin

Continue Co-trimoxazole*

* <u>High bioavailability</u>, use IV only if PO contra-indicated

**If previous *C.difficile* infection discuss with microbiology.

Bone & joint Infections OR Severe Skin & Soft Tissue Infections (SSTI)

Continuing gram negative cover is not always required.

If cultures are still in progress, continue Gentamicin and review with culture results once available.

Intra-abdominal Infections *OR*Sepsis of Unknown Source

- No antimicrobial for 6 months, no ESBL in last 12 months → PO Co-trimoxazole 960mg 12hrly and metronidazole*
- Received antimicrobial in last 6 months, no ESBL in last 12 months → IV Tazocin monotherapy or replace Gentamicin with PO Cotrimoxazole* 960mg 12hrly
- Previous ESBL→ replace
 Gentamicin with IV Temocillin or
 PO Ciprofloxacin** if ESBL
 reported as susceptible

If further advice is required after discussion with an appropriate more senior member of the clinical team, a non-urgent referral to the duty consultant microbiologist can be made by email

Reference: ADTC 378/03 Supersedes: ADTC 378/02 Review Date: 31st July 2025

Written by: Dr Ursula Altmeyer on behalf of Antimicrobial Management Team, Oct 2022

Approved by: Antimicrobial Management Group

Date Approved: 27th July 2022